Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.

Project Information

Syst-Onco-Herpes

Grant agreement ID: 101069392

DOI 10.3030/101069392

Project closed

EC signature date 13 April 2022

Start date 1 May 2022

End date 31 October 2023

Funded under

• European Research Council (ERC)

Total cost No data

EU contribution € 150 000,00

Coordinated by

FONDAZIONE POLICLINICO SANT'ORSOLA ONLUS
Italy

Publications

Peer reviewed articles (2)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses-Clearance and Biodistribution in Naïve and HSV-Preimmune Mice

Author(s): rea Vannini 1,2,†ORCID,Federico Parenti 1,†ORCID,Catia Barboni 3ORCID,Cristina Forghieri 1,Valerio Leoni 1,Mara Sanapo 4,Daniela Bressanin 1,Anna Zaghini 3ORCID,Gabriella Campadelli-Fiume 1,*,‡ andTatiana Gianni 1,*,‡
Published in: Cancers, 2023, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers15164042

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

Author(s): Andrea Vannini1,2 Federico Parenti1 Cristina Forghieri1 Catia Barboni3 Anna Zaghini3 Gabriella Campadelli-Fiume1*†Tatiana Gianni1*†
Published in: Front. Mol. Biosci., 2023, ISSN 2296-889X
Publisher: Frontiers
DOI: 10.3389/fmolb.2023.1149973